BOSTON--(BUSINESS WIRE)--Life Biosciences today announced it is acquiring Lua, the communication and technology platform. This bold step is intended to facilitate the creation of a proprietary artificial intelligence (AI) platform, designed to accelerate Life Biosciences’ research for novel therapies, technologies and drugs to combat age-related decline (ARD). Life Biosciences is the first and largest biotech company focused on addressing health decline due to aging as a systemic breakdown of the body, rather than a series of isolated events and conditions.
Lua is a web- and mobile-access technology platform focused on improving patient outcomes by facilitating communication between providers and patients. Within Life Biosciences, Lua’s technology will be developed into a platform that is expected to allow faster, comprehensive analysis of study data and the integration of information from scientific studies being conducted by each of the ‘Daughter companies’ within Life Biosciences’ Dream Team business model.
This capability will support all of Life Biosciences’ research to help humans and animals live longer, healthier lives, by ensuring better and faster development of drugs and other treatments. Lua’s direct-to-patient communication model is already at work with demanding healthcare providers, such as Aces ABA, Hospice Partners of America, and The Ensign Group.
“Our Daughter companies are led by the world’s most eminent researchers on age-related decline and longevity,” said Tristan Edwards, co-founder and chief executive officer of Life Biosciences. “Their work will extend into human trials, and for that reason we are thrilled to acquire the powerful Lua platform, which will be available to each of our companies as a proven system for communicating in a HIPAA-compliant environment enabling rich interactivity with a user-friendly interface.”
– Lua: Connective Platform –
“We are excited to be joining the Life Biosciences family,” said Michael DeFranco, Lua co-founder. “Lua's focus, to improve outcomes by streamlining access between healthcare providers and patients, fits perfectly with Life Biosciences’ mission to increase healthy lifespans for all. By creating real-time feedback loops, we expect to bring data-led insights to researchers in clinical trials that were not feasible earlier. We firmly believe our direct-to-consumer technology has the potential to change pet and ultimately human life as we know it.”
Lua, founded in 2010, will continue to be operated as a separate company by its co-founders, DeFranco and Jason Krigsfeld. Beyond its primary role in healthcare, the company’s platform is also available to enterprise customers in financial services, hospitality and event planning. Its intuitive and real-time architecture allows for team-based and customer-based communication.
Nick Ventresca, chief technology officer of Life Biosciences, noted, “All drug development is based upon the insightful and privacy-protective use of data and information. We will utilize the Lua platform for not only drug development, but also in the future to securely bring information to patients and caregivers around the world.”
– Life Biosciences Overview –
Life Biosciences was co-founded in 2017 by David Sinclair, PhD, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, who developed its innovative structure as Chapter Two in his life, after a highly successful career as a global institutional investor, working across all asset classes.
The company’s novel Daughter company business model creates the robust research ecosystem required to forge industry leadership through two investment strategies. The first is to establish new companies, thereby extending the research of visionary scientists around the world. Secondly, Life Biosciences invests in other groundbreaking firms, providing them with the resources to maximize their potential.
In addition to Lua, there are six Daughter companies working independently and together within the Life Biosciences research environment. The company provides Daughter companies with the resources required to maximize human potential, including Lua’s AI-driven data and communications platform, experienced management, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass, augmented by laboratories and offices on four continents.
Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest biotech company addressing the eight pathways of age-related decline (ARD) in totality. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with resources to maximize human potential, including Lua’s AI-driven data and communications platform, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility. Life Biosciences seeks to increase healthspans for everyone, including companion animals, by addressing the systemic breakdown of the body, rather than as a series of isolated symptoms and conditions.
For more information on Life Biosciences, please visit www.lifebiosciences.com.